Literature DB >> 1884380

Cancer dormancy: studies of the murine BCL1 lymphoma.

J W Uhr1, T Tucker, R D May, H Siu, E S Vitetta.   

Abstract

Dormancy in the murine BCL1 lymphoma can be induced by several strategies including cytoreductive therapy of mice with large tumor burdens and challenge of allogeneic chimeric mice or idiotype-immunized mice with BCL1 tumor. Dormant tumor cells were isolated from the spleens of the chimeric mice and the majority were shown to be noncycling. In idiotype-immunized mice that had lost dormancy, tumor growth occurred at a relatively rapid rate. A proportion of idiotype-immunized mice that had lost dormancy spontaneously regressed and then again relapsed; in these mice, the serum antiidiotypic levels were inversely related to the tumor burden.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1884380

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

Review 1.  Melanoma vaccines. Current status and future prospects.

Authors:  P Hersey
Journal:  Drugs       Date:  1994-03       Impact factor: 9.546

2.  Time-varying pattern of recurrence risk for gastric cancer patients.

Authors:  Xing-Yu Feng; Ying-Bo Chen; Wei Wang; Yuan-Xiang Guan; Yuan-Fang Li; Shi Chen; Xiao-Wei Sun; Wei Li; Da-Zhi Xu; You-Qing Zhan; Xiao-Shi Zhang; Zhi-Wei Zhou
Journal:  Med Oncol       Date:  2013-02-24       Impact factor: 3.064

Review 3.  Controversies in clinical cancer dormancy.

Authors:  Jonathan W Uhr; Klaus Pantel
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-11       Impact factor: 11.205

4.  Cancer dormancy and cell signaling: induction of p21(waf1) initiated by membrane IgM engagement increases survival of B lymphoma cells.

Authors:  R Marches; R Hsueh; J W Uhr
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

5.  Detection and characterization of carcinoma cells in the blood.

Authors:  E Racila; D Euhus; A J Weiss; C Rao; J McConnell; L W Terstappen; J W Uhr
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-14       Impact factor: 11.205

6.  STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy.

Authors:  Lekh N Dahal; Lang Dou; Khiyam Hussain; Rena Liu; Alexander Earley; Kerry L Cox; Salome Murinello; Ian Tracy; Francesco Forconi; Andrew J Steele; Patrick J Duriez; Diego Gomez-Nicola; Jessica L Teeling; Martin J Glennie; Mark S Cragg; Stephen A Beers
Journal:  Cancer Res       Date:  2017-05-16       Impact factor: 12.701

7.  Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis.

Authors:  V A Kuznetsov; I A Makalkin; M A Taylor; A S Perelson
Journal:  Bull Math Biol       Date:  1994-03       Impact factor: 1.758

Review 8.  Interferon-gamma and cancer immunoediting.

Authors:  Gavin P Dunn; Hiroaki Ikeda; Allen T Bruce; Catherine Koebel; Ravi Uppaluri; Jack Bui; Ruby Chan; Mark Diamond; J Michael White; Kathleen C F Sheehan; Robert D Schreiber
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

9.  Mathematical models of immune-induced cancer dormancy and the emergence of immune evasion.

Authors:  Kathleen P Wilkie; Philip Hahnfeldt
Journal:  Interface Focus       Date:  2013-08-06       Impact factor: 3.906

10.  Cancer dormancy: isolation and characterization of dormant lymphoma cells.

Authors:  E Yefenof; L J Picker; R H Scheuermann; T F Tucker; E S Vitetta; J W Uhr
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.